7

1 Supplemental Figures

Supplemental Figures · Supplemental Figure 4. Mouse target organ histology and flow cytometry characteristics for syngeneic and allogeneic hematopoietic stem cell transplant (HSCT)

Download PDF Report

Upload
others
View
5
Download
0

Embed Size (px)

Citation preview

Page 1: Supplemental Figures · Supplemental Figure 4. Mouse target organ histology and flow cytometry characteristics for syngeneic and allogeneic hematopoietic stem cell transplant (HSCT)

1

SupplementalFigures

Page 2: Supplemental Figures · Supplemental Figure 4. Mouse target organ histology and flow cytometry characteristics for syngeneic and allogeneic hematopoietic stem cell transplant (HSCT)

2

Page 3: Supplemental Figures · Supplemental Figure 4. Mouse target organ histology and flow cytometry characteristics for syngeneic and allogeneic hematopoietic stem cell transplant (HSCT)

3

Page 4: Supplemental Figures · Supplemental Figure 4. Mouse target organ histology and flow cytometry characteristics for syngeneic and allogeneic hematopoietic stem cell transplant (HSCT)

4

Page 5: Supplemental Figures · Supplemental Figure 4. Mouse target organ histology and flow cytometry characteristics for syngeneic and allogeneic hematopoietic stem cell transplant (HSCT)

5

Page 6: Supplemental Figures · Supplemental Figure 4. Mouse target organ histology and flow cytometry characteristics for syngeneic and allogeneic hematopoietic stem cell transplant (HSCT)

6

Page 7: Supplemental Figures · Supplemental Figure 4. Mouse target organ histology and flow cytometry characteristics for syngeneic and allogeneic hematopoietic stem cell transplant (HSCT)

7

2019: Waldenstrom's Macroglobulinemia Pre- HSCT Data

2019: Waldenstrom's Macroglobulinemia Pre- HSCT Data

Documents

Pharmacokinetics and Pharmacodynamics of Posaconazole · AML/MDS Allogeneic HSCT SICU AML/MDS HV,IMD (48%HSCT) HM HV,AML/MDS/ HSCT IMD HV,AML/MDS/ HSCT,clinical trials Numberofindi-215

Pharmacokinetics and Pharmacodynamics of Posaconazole · AML/MDS Allogeneic HSCT SICU AML/MDS HV,IMD (48%HSCT) HM HV,AML/MDS/ HSCT IMD HV,AML/MDS/ HSCT,clinical trials Numberofindi-215

Documents

Teratoma Formation in Immunocompetent Mice After Syngeneic and

Teratoma Formation in Immunocompetent Mice After Syngeneic and

Documents

Characterization of a MC38 Mouse Syngeneic Tumor Model ... · Characterization of a MC38 Mouse Syngeneic Tumor Model Expressing Human PD-L1 in the ... PD-L1), Biolegend (Cat 124311)

Characterization of a MC38 Mouse Syngeneic Tumor Model ... · Characterization of a MC38 Mouse Syngeneic Tumor Model Expressing Human PD-L1 in the ... PD-L1), Biolegend (Cat 124311)

Documents

Epstein-Barr Virus (EBV) complications following HSCT ... Virus (EBV) complications following HSCT: from viremia to pppyppost transplant lymphoproliferative disease (PTLD) and lymphoma

Epstein-Barr Virus (EBV) complications following HSCT ... Virus (EBV) complications following HSCT: from viremia to pppyppost transplant lymphoproliferative disease (PTLD) and lymphoma

Documents

Azacitidine in AML/MDS after allogeneic HSCT

Azacitidine in AML/MDS after allogeneic HSCT

Documents

Syngeneic Models - Oncodesign · Syngeneic Models at Oncodesign Model Organ Host rodent species Injection site ... A20 B cell lymphoma Model Mice were SC injected with A20 tumor cells

Syngeneic Models - Oncodesign · Syngeneic Models at Oncodesign Model Organ Host rodent species Injection site ... A20 B cell lymphoma Model Mice were SC injected with A20 tumor cells

Documents

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic …eprints.whiterose.ac.uk/113007/7/Syngeneic manuscript... · 2018-03-21 · Rational selection of

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic …eprints.whiterose.ac.uk/113007/7/Syngeneic manuscript... · 2018-03-21 · Rational selection of

Documents

Allogeneic HSCT for Myelodysplastic Syndromes and ... · myelodysplastic syndromes and myeloproliferative ... 3.2 Polycythemia ... Allogeneic HSCT for Myelodysplastic Syndromes and

Allogeneic HSCT for Myelodysplastic Syndromes and ... · myelodysplastic syndromes and myeloproliferative ... 3.2 Polycythemia ... Allogeneic HSCT for Myelodysplastic Syndromes and

Documents

Engraftment Monitoring after HSCT · 2018-04-01 · Patients with MC level 3 early after HSCT have a higher risk of graft rejection Engraftment status at 60 days after HSCT Patients

Engraftment Monitoring after HSCT · 2018-04-01 · Patients with MC level 3 early after HSCT have a higher risk of graft rejection Engraftment status at 60 days after HSCT Patients

Documents

Acute Myelogenous Leukemia Pre-HSCT Data - Center for

Acute Myelogenous Leukemia Pre-HSCT Data - Center for

Documents

Syngeneic Schwann Cells Derived from Adult Nerves Seeded in … · 2003-10-29 · The Journal of Neuroscience, September 1992, l,?(9): 33103320 Syngeneic Schwann Cells Derived from

Syngeneic Schwann Cells Derived from Adult Nerves Seeded in … · 2003-10-29 · The Journal of Neuroscience, September 1992, l,?(9): 33103320 Syngeneic Schwann Cells Derived from

Documents

NEW APPROACHES TO HSCT MULTIDISCIPLINARY DESIGN … · new approaches to hsct multidisciplinary design and optimization ... year 3 objectives and results ... (ippd) philosophy). often

NEW APPROACHES TO HSCT MULTIDISCIPLINARY DESIGN … · new approaches to hsct multidisciplinary design and optimization ... year 3 objectives and results ... (ippd) philosophy). often

Documents

CIC: Patient UIC yyyy - mm - dd HSCT - Minimum Essential ... · CIC: Hospital UPN: HSCT Date: yyyy - mm - dd Patient UIC Status At HSCT Adjuvant Never treated (upfront) Stable disease/no

CIC: Patient UIC yyyy - mm - dd HSCT - Minimum Essential ... · CIC: Hospital UPN: HSCT Date: yyyy - mm - dd Patient UIC Status At HSCT Adjuvant Never treated (upfront) Stable disease/no

Documents

Mouse Renca Renal Cell Carcinoma Syngeneic Model to ... · Mouse Renca Renal Cell Carcinoma Syngeneic Model to Evaluate Efficacy of Novel Antisense Oligonucleotides Targeting Transforming

Mouse Renca Renal Cell Carcinoma Syngeneic Model to ... · Mouse Renca Renal Cell Carcinoma Syngeneic Model to Evaluate Efficacy of Novel Antisense Oligonucleotides Targeting Transforming

Documents

Marché - consultants HSCT

Marché - consultants HSCT

Documents

Transfusion in hsct

Transfusion in hsct

Documents

ID8-Luc syngeneic ovarian cancer model for preclinical

ID8-Luc syngeneic ovarian cancer model for preclinical

Documents

Allo -HSCT for ALL

Allo -HSCT for ALL

Documents

yyyy mm dd Patient Number in EBMT database (if … · If you are reporting a subsequent HSCT, treatment refers to any non HSCT treatment given after the last HSCT reported. Treatment

yyyy mm dd Patient Number in EBMT database (if … · If you are reporting a subsequent HSCT, treatment refers to any non HSCT treatment given after the last HSCT reported. Treatment

Documents

Hematopoietic Stem Cell Transplantation (HSCT) · PDF fileHematopoietic Stem Cell Transplantation (HSCT) Overview Willis H Navarro, MD Medical Director, Transplant Services, NMDP Associate

Hematopoietic Stem Cell Transplantation (HSCT) · PDF fileHematopoietic Stem Cell Transplantation (HSCT) Overview Willis H Navarro, MD Medical Director, Transplant Services, NMDP Associate

Documents

Module 1 hsct it

Module 1 hsct it

Documents

HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) …€¦ · Haematopoietic Stem Cell Transplantation (HSCT) Guide for Patients and Caregivers FOREWORD HAEMATOPOIETIC STEM CELL TRANSPLANTATION

HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) …€¦ · Haematopoietic Stem Cell Transplantation (HSCT) Guide for Patients and Caregivers FOREWORD HAEMATOPOIETIC STEM CELL TRANSPLANTATION

Documents

Managing MF and SS with Allogeneic HSCT - Cutaneous …cutaneouslymphoma.stanford.edu/documents/SY58 allo HSCT in MFSS… · Managing MF and SS with Allogeneic HSCT Youn H Kim, MD

Managing MF and SS with Allogeneic HSCT - Cutaneous …cutaneouslymphoma.stanford.edu/documents/SY58 allo HSCT in MFSS… · Managing MF and SS with Allogeneic HSCT Youn H Kim, MD

Documents

Diverse immunotherapies can effectively treat syngeneic ...RESEARCH ARTICLE Open Access Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt

Diverse immunotherapies can effectively treat syngeneic ...RESEARCH ARTICLE Open Access Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt

Documents

Documents

Allogeneic HSCT in Elderly

Allogeneic HSCT in Elderly

Education

INTRODUCTION TO HAEMATOPOIETIC STEM CELL TRANSPLANT(HSCT)

INTRODUCTION TO HAEMATOPOIETIC STEM CELL TRANSPLANT(HSCT)

Documents

Sensitivity of Syngeneic Tumor Models to Focal Radiation

Sensitivity of Syngeneic Tumor Models to Focal Radiation

Documents

Séminaire HSCT

Documents